BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 30905548)

  • 21. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
    Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
    Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical treatment for cholangiocarcinoma.
    Adeva J; Sangro B; Salati M; Edeline J; La Casta A; Bittoni A; Berardi R; Bruix J; Valle JW
    Liver Int; 2019 May; 39 Suppl 1():123-142. PubMed ID: 30892822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and emerging therapies for advanced biliary tract cancers.
    Kam AE; Masood A; Shroff RT
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
    Alsina M; Moehler M; Lorenzen S
    Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infigratinib in patients with advanced cholangiocarcinoma with
    Makawita S; K Abou-Alfa G; Roychowdhury S; Sadeghi S; Borbath I; Goyal L; Cohn A; Lamarca A; Oh DY; Macarulla T; T Shroff R; Howland M; Li A; Cho T; Pande A; Javle M
    Future Oncol; 2020 Oct; 16(30):2375-2384. PubMed ID: 32580579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
    I Ilyas S; Borad MJ; Patel T; Gores GJ
    Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.
    Borger DR; Zhu AX
    Expert Rev Anticancer Ther; 2012 May; 12(5):543-6. PubMed ID: 22594888
    [No Abstract]   [Full Text] [Related]  

  • 30. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
    Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
    Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholangiocarcinoma: investigations into pathway-targeted therapies.
    Ntanasis-Stathopoulos I; Tsilimigras DI; Gavriatopoulou M; Schizas D; Pawlik TM
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):765-773. PubMed ID: 32757962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
    Brown ZJ; Ruff SM; Pawlik TM
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
    J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Medical management of cholangiocarcinomas in 2015].
    Marret G; Neuzillet C; Rousseau B; Tournigand C
    Bull Cancer; 2016 Apr; 103(4):389-99. PubMed ID: 26922666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
    Jensen LH; Jakobsen A
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
    Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
    PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
    Blair AB; Murphy A
    Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets.
    Tariq NU; Vogel A; McNamara MG; Valle JW
    Oncol Res Treat; 2018; 41(5):298-304. PubMed ID: 29705791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab.
    Naganuma A; Sakuda T; Murakami T; Aihara K; Watanuki Y; Suzuki Y; Shibasaki E; Masuda T; Uehara S; Yasuoka H; Hoshino T; Kudo T; Ishihara H; Ogawa T; Kitamoto Y; Ogawa A
    Intern Med; 2020 Sep; 59(18):2261-2267. PubMed ID: 32536644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.